Optimization of MSC therapeutic strategies for improved GVHD treatment  

作　　者：Hanyu Wang Weihong Kuang 

机构地区：[1]The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

出　　处：《国际感染病学（电子版）》2017年第1期1-7,共7页Infection International(Electronic Edition)

摘　　要：Mesenchymal stem cells(MSCs) have a powerful immunosuppressive capacity, and they have been used to treat numerous immune diseases, such as refractory graft-versus-host disease. Nevertheless, there are conflicting clinical data. To our knowledge, MSCs from different donors do not share the same qualities and have different immunosuppressive capacities. Infused MSCs are cleared by the recipient's immune cells or macrophages. Therefore, the MSC therapeutic strategy might be the most important factor that determines treatment success. Repeated infusions would lead to a relatively stable MSC concentration, which would benefit a sustained therapeutic effect. In this review, we focus on the quality of MSCs and the associated therapeutic strategy, as well as other potential variables affecting their utility as a cellular pharmaceutical.Mesenchymal stem cells(MSCs) have a powerful immunosuppressive capacity, and they have been used to treat numerous immune diseases, such as refractory graft-versus-host disease. Nevertheless, there are conflicting clinical data. To our knowledge, MSCs from different donors do not share the same qualities and have different immunosuppressive capacities. Infused MSCs are cleared by the recipient's immune cells or macrophages. Therefore, the MSC therapeutic strategy might be the most important factor that determines treatment success. Repeated infusions would lead to a relatively stable MSC concentration, which would benefit a sustained therapeutic effect. In this review, we focus on the quality of MSCs and the associated therapeutic strategy, as well as other potential variables affecting their utility as a cellular pharmaceutical.

关 键 词：MESENCHYMAL STEM cell GRAFT-VERSUS-HOST DISEASE systematic review 

分 类 号：R457.7[医药卫生—治疗学]